Revolutionizing Type 2 Diabetes Treatment: Endogenex Secures $88M in Series C Funding

Endogenex, a pioneering clinical-stage company based in Minneapolis, MN, is thrilled to announce a significant funding milestone, having raised an impressive $88 million in its latest funding round. In collaboration with the esteemed Mayo Clinic, Endogenex is on a mission to revolutionize treatment options for individuals battling type 2 diabetes (T2D). The innovative company focuses on resetting the body’s metabolic signaling system, tapping into its innate regenerative capabilities to enhance metabolic function. Central to this groundbreaking approach is the development of the ReCET™ System, which utilizes precise, controlled, non-thermal pulsed electric fields. This novel technology marks the dawn of a new therapeutic era, empowering patients with T2D to regain mastery over their blood glucose levels while simultaneously slowing disease progression. The newly secured funds will be pivotal in propelling Endogenex’s research and development efforts, advancing clinical trials, and ultimately bringing this transformative treatment to patients in need. Given the rising prevalence of type 2 diabetes and the limitations of current treatment options, the potential impact of Endogenex's innovations extends beyond the company itself—it could substantially improve the lives of millions affected by this chronic condition. With this funding, Endogenex is one step closer to achieving its vision of a world where individuals with T2D can lead healthier, more fulfilling lives.